Sort by
Keyphrases
Systemic Sclerosis
100%
Nailfold Capillaroscopy
66%
Pediatric Patients
66%
Kawasaki Disease
66%
Rheumatoid Arthritis
58%
Biologic Therapy
58%
Anti-tumor Necrosis Factor (anti-TNF)
41%
Clinical Trials
38%
High-density Lipoprotein Cholesterol (HDL-C)
33%
Secondary Raynaud's Phenomenon
33%
Observational Prospective Cohort Study
33%
Primary Raynaud's Phenomenon
33%
Extended-release Niacin
33%
Antioxidant Effect
33%
Anti-interleukin-6 Receptor
33%
Nontumor
33%
Tumor Necrosis Factor-α
33%
Apolipoprotein A-I (ApoA-I)
33%
Infection Risk
33%
Notch Pathway
33%
Confinement Measures
33%
Seroconversion
33%
Interstitial Lung Disease
33%
Monoclonal Antibody
33%
COVID-19
33%
Iron Metabolism
33%
Confidence Interval
29%
Anti-IL-6 Receptor
25%
Capillary
24%
Coefficient Estimates
18%
Capillary Loss
18%
Biologic Disease-modifying Antirheumatic Drugs
16%
Medical Intervention
16%
Therapeutic Regimen
16%
Rheumatoid Arthritis Treatment
16%
Adult-onset Kawasaki Disease
16%
Cardiac Damage
16%
Disease Activity
16%
Essential Workers
16%
Serum Iron
16%
Paucisymptomatic
16%
Serum IgE
16%
IgA Antibody
16%
SARS-CoV-2 Infection
16%
Transferrin Saturation
16%
Pathophysiology
16%
University of Lisbon
16%
Tocilizumab
16%
Cardiovascular Complications
16%
Early Detection
16%
Pharmacology, Toxicology and Pharmaceutical Science
Systemic Sclerosis
100%
Rheumatoid Arthritis
52%
Inflammatory Arthritis
52%
Clinical Trial
38%
Diseases
38%
Biological Product
38%
Tumor Necrosis Factor
33%
Antioxidant
33%
Apolipoprotein A
33%
Nicotinic Acid
33%
Raynaud Phenomenon
33%
Interstitial Lung Disease
33%
Interleukin 6 Receptor
33%
High Density Lipoprotein Cholesterol
33%
Monoclonal Antibody
33%
Infection
33%
Iron
33%
Prospective Cohort Study
33%
Pathophysiology
20%
Receptor
19%
Interleukin 6
19%
Disease Modifying Antirheumatic Drug
11%
Disease Activity
11%
Fibrosis
11%
Tocilizumab
9%
Transferrin
9%
Edema
9%
Antioxidant Capacity
6%
Aryldialkylphosphatase 1
6%
Medicine and Dentistry
Kawasaki Disease
66%
Pediatrics Patient
66%
Infection
33%
Iron Metabolism
33%
Interstitial Lung Disease
33%
Interleukin 6 Receptor
33%
Systemic Scleroderma
33%
Monoclonal Antibody
33%
Capillary
29%
Inflammatory Arthritis
19%
Interleukin 6
19%
Rheumatoid Arthritis
19%
Receptor
19%
Biological Therapy
14%
Immunoglobulin
13%
Cardiovascular Disease
13%
Awareness
13%
Diagnostic Delay
13%
Cardiovascular System
13%
Diagnostic Criterion
13%
Serositis
13%
Heart Injury
13%
Coronary Artery Aneurysm
13%
DLCO
11%
Forced Vital Capacity
11%
Transferrin Saturation
9%
Tocilizumab
9%
Serum Iron
9%
Odds Ratio
7%
